Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Study Agent Clear all
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Determinants of POTS - Pilot1

NCT04050410
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Active, not recruiting Phase 1 Interventional

Rapid Administration Pilot for Infusing Dinutuximab

NCT05421897
View directory record Official record
Conditions
Neuroblastoma
Interventions
Dinutuximab with Chemotherapy
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

NCT02651324
View directory record Official record
Conditions
Idiopathic Scoliosis, Post-operative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

NCT01453023
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Furoate/Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Huntington Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 1 Interventional

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT01308580
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 9, 2026, 2:02 AM EDT
Withdrawn Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase

NCT03791580
View directory record Official record
Conditions
Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
Interventions
Commitment nudge, Justification nudge
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Active, not recruiting Phase 1 Interventional

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

NCT05621096
View directory record Official record
Conditions
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Bridging radiation therapy, Liso-cel, Post-infusion radiation
Radiation · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study in Patients With Advanced Cancers

NCT05320588
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Interventions
BIO-106, Pembrolizumab
Drug
Lead sponsor
BiOneCure Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Austin, Texas • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 9, 2026, 2:02 AM EDT
Completed No phase listed Observational Results available

TAXUS Libertē Post Approval Study

NCT00997503
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
4,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
82
States / cities
Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 9, 2026, 2:02 AM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib and Letrozole to Treat Endometrial Cancer

NCT04393285
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Midazolam, Rosuvastatin, Caffeine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 2 Interventional

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

NCT06764615
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Glen Burnie, Maryland • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00075374
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

NCT05421013
View directory record Official record
Conditions
Facial isSCC
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Early Phase 1 Interventional

AvenovaTM as a Sterile Skin Preparation Agent

NCT02990013
View directory record Official record
Conditions
Cleaning Product Causing Toxic Effect
Interventions
Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 3 Interventional

Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma

NCT00907413
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
ERCP and Photodynamic Therapy, ERCP only
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotteville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 2

NCT03888482
View directory record Official record
Conditions
Refractive Error, Myopia
Interventions
Verofilcon A contact lenses, Somofilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
8
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Withdrawn Phase 4 Interventional

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

NCT03026023
View directory record Official record
Conditions
Cardiac Transplant Disorder, Hepatitis C
Interventions
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 9, 2026, 2:02 AM EDT